SCHEDULE 13D: Quoin Pharmaceuticals COO Denise Carter Boosts Stake to 6.9% Following Public Offering and Option Grants

Quoin Pharmaceuticals Ltd.'s Chief Operating Officer, Denise Carter, has increased her beneficial ownership in the company to 6.9% through recent share purchases in a public offering and new option grants, as detailed in a Schedule 13D filing.

Summary

• Denise Carter, Chief Operating Officer of Quoin Pharmaceuticals Ltd., reported beneficial ownership of 622,413 American Depositary Shares (ADSs), representing 6.9% of the company's outstanding Ordinary Shares as of December 23, 2024.
• Her beneficial ownership includes 602,648 directly held ADSs and 19,765 ADSs issuable from outstanding options within 60 days of the filing.
• The reported percentage is calculated based on 8,948,164 Ordinary Shares outstanding as of December 23, 2024.
• On December 23, 2024, Ms. Carter purchased 555,556 ADSs, along with 555,556 Series F Warrants and 555,556 Series G Warrants, in the Issuer's public offering at a combined price of $0.45 per ADS.
• On December 9, 2024, she was granted an option to purchase 536,609 ADSs at an exercise price of $0.78, which is not exercisable within 60 days of the filing.
• She also holds other outstanding options from April 12, 2022 (7,143 shares at $210 exercise price) and October 26, 2023 (80,966 shares at $5.75 exercise price), with portions already vested.
• The Series F and G Warrants have an exercise price of $0.45 per share and are immediately exercisable, but are subject to a 4.99% ownership blocker, preventing exercise if it would result in ownership exceeding this threshold.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the Chief Operating Officer's increased beneficial ownership, including participation in a public offering and significant new option grants, which signals confidence. However, the presence of a 4.99% ownership blocker on a large portion of warrants and the significantly higher exercise prices of older options compared to recent transactions temper the overall positive outlook.

Positives

• Increased insider ownership by the Chief Operating Officer, Denise Carter, which can signal confidence in the company's future prospects and strategic direction.
• Acquisition of shares and warrants through a public offering, indicating direct participation in the company's capital raising efforts and commitment.
• Grant of significant new stock options to the COO, aligning management incentives with shareholder interests and potential long-term value creation.

Negatives

• The 4.99% ownership blocker on Series F and G Warrants limits the immediate exercisability and potential beneficial ownership increase from these instruments, restricting the full impact of the warrant holdings.
• The exercise price of some older options ($210 and $5.75) is significantly higher than the recent public offering price ($0.45) and the newest option grant price ($0.78), suggesting a substantial decline in the company's share value since those grants.

Risks

• Ownership Blocker on Warrants: The Series F and G Warrants held by the Reporting Person are not exercisable within 60 days due to a 4.99% ownership blocker, limiting the immediate increase in beneficial ownership from these instruments.
• No Trading Market for Warrants: There is no expected trading market for the Series F and G Warrants, which could limit liquidity and the ability to monetize these instruments.
• Potential Dilution from Future Exercises: The vesting of unvested options and potential exercise of warrants could lead to future dilution for existing shareholders as new shares are issued.

Future Outlook

The Reporting Person, as a director and Chief Operating Officer, will regularly consider potential actions and transactions advantageous to the Issuer, including possible mergers, acquisitions, reorganizations, or other material changes. She may also acquire additional securities through the exercise or vesting of existing options and warrants, new option grants, or open market purchases if market conditions are favorable.

Management Comments

• "The Ordinary Shares reported herein as beneficially owned by the Reporting Person were acquired by the Reporting Person for investment purposes."
• "As a director and Chief Operating Officer of the Issuer, the Reporting Person will regularly consider potential actions and transactions that may be advantageous to the Issuer, including possible mergers, acquisitions, reorganizations or other material changes in the business, corporate structure, management, policies, governing instruments, securities or regulatory or reporting obligations of the Issuer."
• "The Reporting Person does not have any present plans or proposals that relate to or would result in any extraordinary corporate transaction, changes in management, capitalization, or corporate structure, or delisting of securities."

Industry Context

This Schedule 13D filing reflects an insider's increased stake in a pharmaceutical company. While specific industry trends are not detailed, such filings are common in the biotech and pharmaceutical sectors, where management's long-term commitment and belief in pipeline development are crucial. The public offering and warrant issuance suggest a recent capital raise, a common occurrence for development-stage pharmaceutical companies requiring funding for R&D and clinical trials.

Related Party Transactions

• The purchase of 555,556 ADSs, Series F Warrants, and Series G Warrants by Denise Carter, the Chief Operating Officer, in the Issuer's public offering on December 23, 2024, can be considered a related party transaction.
• The grant of 536,609 ADSs as an option to Ms. Carter on December 9, 2024, is also a related party transaction as it involves compensation to an executive.

Stakeholder Impact

• Shareholders: The increased insider ownership may be viewed positively as a sign of management confidence. However, future exercise of options and warrants could lead to dilution of existing shares.
• Employees: The grant of options to the COO aligns her incentives with the company's performance, potentially benefiting all employees through a more focused and motivated leadership.
• Creditors: The capital raise implied by the public offering could improve the company's financial liquidity and balance sheet, potentially benefiting creditors by strengthening the company's ability to meet its obligations.

Next Steps

• Vesting of unvested options will increase the Reporting Person's beneficial ownership of Ordinary Shares over time.
• The Reporting Person may acquire additional securities through the exercise of currently held options or warrants.
• The Reporting Person may acquire additional securities through the vesting of currently held options.
• The Reporting Person may acquire additional securities through the grant of additional options by the Issuer.
• The Reporting Person may acquire additional securities from time to time in open market purchases for investment purposes if market conditions are favorable.

Key Dates

Keywords

Quoin Pharmaceuticals, QPHY, Denise Carter, Schedule 13D, beneficial ownership, stock options, warrants, public offering, insider ownership, corporate governance, SEC filing, pharmaceutical